Volume 7.30 | Aug 6

Mammary Cell News 7.30 August 6, 2015
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
New Cancer Marker Identified; Possible Therapeutic Target for Breast Cancer
Researchers compared the markers on the surface of the cancer cells to gene expression profile of breast tumors deposited by researchers in international public databases and found that a molecule named IL13RA2 was abundant in metastatic or late-stage basal-like breast cancer. [Press release from Boston University Medical Center (EurekaAlert!) discussing online prepublication in Breast Cancer Research]
Press Release | Full Article
MammoCult™: Most Published Mammosphere & Tumorsphere Culture Medium (Commercially Available) FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

BCRP and P-Gp Relay Overexpression in Triple Negative Basal-Like Breast Cancer Cell Line: A Prospective Role in Resistance to Olaparib
Investigators focused on the analysis of P-gp and BCRP coexpression in the SUM1315 triple negative basal-like human cell line, in correlation with Olaparib intracellular concentration. [Sci Rep] Full Article

Human Breast Cancer Cells Educate Macrophages toward the M2 Activation Status
Scientists demonstrated ex vivo that breast cancer cell-secreted factors modulate macrophage differentiation toward the M2 phenotype. The more aggressive mesenchymal-like cell line MDA-MB231, which secretes high levels of M-CSF, skews macrophages toward the more immunosuppressive M2c subtype. [Breast Cancer Res] Full Article

Mammaglobin 1 Promotes Breast Cancer Malignancy and Confers Sensitivity to Anticancer Drugs
Using a series of breast cancer cell models with conditional mammaglobin 1 (MGB1) expression, researchers demonstrated that MGB1 promotes cancer cell malignant features. More specifically, loss of MGB1 expression resulted in a decrease of cell proliferation, soft agar spheroid formation, migration, and invasion capacities of breast cancer cells. [Mol Carcinog] Abstract

Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Breast Cancer Chemotherapy
Breast cancer cells were treated with NR4A1 antagonists or transfected with siNR4A, and effects on cell proliferation and apoptosis and specific genes associated with these responses were investigated in MCF-7, SKBR3 and MDA-MB-231 cells and in athymic nude mice bearing MDA-MB-231 cells as xenografts. [Endocr Relat Cancer] Abstract

Neoplastic Transformation of Porcine Mammary Epithelial Cells In Vitro and Tumor Formation In Vivo
Researchers established a model for the efficient manipulation and transformation of porcine mammary epithelial cells in vitro and tumor growth in vivo. [BMC Cancer] Full Article

Interactions between αv-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain
Scientists tested the hypothesis that αv-integrin and the human epidermal growth factor receptor type 2 (HER2) interact with each other in brain trophic metastatic breast cancer cells and influence their invasive phenotype. [PLoS One] Full Article

β-Adrenergic Receptors Suppress Rap1B Prenylation and Promote the Metastatic Phenotype in Breast Cancer Cells
The authors investigated whether the general Gαs activator, cholera toxin, and agonists of the β-adrenergic receptor (βAR), which is a Gαs-coupled GPCR, promote Rap1B phosphorylation and inhibit its prenylation. They showed here that cholera toxin and βAR activation phosphorylated Rap1B and inhibited its prenylation and membrane localization, reducing cell-cell adhesion and promoting cell scattering. [Cancer Biol Ther] Abstract

Synergistic Suppression of Human Breast Cancer Cells by Combination of Plumbagin and Zoledronic Acid In Vitro
Researchers investigated the effects of zoledronic acid (ZA) combined with a natural anticancer compound plumbagin (PL) against human breast cancer cells in vitro. Human breast cancer MDA-MB-231SArfp cells were treated with ZA, PL or a combination of ZA and PL. [Acta Pharmacol Sin] Abstract


Relative Effectiveness of Letrozole Compared with Tamoxifen for Patients with Lobular Carcinoma in the BIG 1-98 Trial
Researchers evaluated the relative effectiveness of letrozole compared with tamoxifen for patients with invasive ductal or lobular carcinoma. [J Clin Oncol] Abstract

Request a Copy: Breast Cancer Wallchart
Roche’s Perjeta Regimen Approved in Europe for Use Before Surgery in Early Stage Aggressive Breast Cancer
Roche announced that the European Commission has approved the use of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. [F. Hoffmann-La Roche Ltd] Press Release

Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Advanced Breast Cancer
Eisai Co., Ltd. and Halozyme Therapeutics, Inc. announced that they have signed a clinical collaboration agreement to evaluate Eisai’s anticancer agent eribulin mesylate in combination with Halozyme’s investigational new drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative advanced breast cancer. [Eisai Co., Ltd.] Press Release

Moffitt Cancer Center Teams Up with MD Anderson to Discover, Test Novel Agents to Prevent Cancer
Moffitt Cancer Center has joined MD Anderson’s National Cancer Institute (NCI) Phase 0/I/II Cancer Prevention Clinical Chemoprevention Trials Consortia. Sponsored by the NCI’s Division of Cancer Prevention, the consortia conducts early clinical development of promising new preventive agents through its Phase 0/I/II Cancer Prevention Clinical Trials Program. [Moffitt Cancer Center (Newswise, Inc.)] Press Release

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW ISCBC 2015: International Stem Cell Biology Conference
October 11-12, 2015
Osaka, Japan

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Researcher – Translational Breast Cancer Research (Dublin City University)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Cancer Biology (Northwestern University)

Postdoctoral Position – Inflammation & Breast Tumor Metastasis (Stephenson Cancer Center)

Postdoctoral Fellow – Cancer Research (National University of Singapore)

Senior Product Manager – Breast Cancer (Celgene Corporation)

Postdoctoral Research Fellow (Fred Hutchinson Cancer Research Center)

Research Associate/Assistant Professor – Breast Cancer (University of Chicago)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Postdoctoral Fellow – Oncolytic Viruses (Mayo Clinic – Rochester)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us